Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treating Early Stage Diabetic Retinopathy
NCT05132660Phase 1Enrolling by invitation
- Sponsor
- VA Office of Research & Development
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of levodopa in diabetic retinopathy (DR) (3 arms), sponsored by VA Office of Research & Development. Primary endpoint: Electroretinogram at 24 months. Started Jul 2022; status: enrolling by invitation.
02
Drugs
levodopa
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05132660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132660.